



## Giuseppe Curigliano

### Contact

Giuseppe Curigliano

## Publications (3)

Jhaveri K, De Vita S, Crystal A, He W, Ji Y, Balbin A, Sheng Q, Kundamal N, Huober J, Takahashi S, Terret C, Duhoux F, Layman R, Cresta S, Yap Y, Juric D, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. *Clin Cancer Res* 2021

Heinhuis K, Schilder R, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Britschgi C, Paz-Ares L, Carlino M, Jörger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J, Siu L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. *JAMA Oncol* 2019:1-8.

Pruneri G, Regan M, Gelber R, Munzone E, Canello G, Price K, Kammler R, Goldhirsch A, Gianni L, Ruhstaller T, Láng I, Criscitiello C, Curigliano G, Viale G, Vingiani A, Gray K, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat* 2016; 158:323-31.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)